Crosstalk between the PI3K/proteinkinase B (Akt) and the MEK1/2-ERK1/2signaling pathways may play a role in cancer, leading to therapeuticstrategies involving combinations of inhibitors to target both. This evidence concerns the gene MAP2K1 and cancer.